The new name aligns with the company’s core technology – transdermal absorption of pharmaceutical agents.
Promescent, which employs a proprietary, eutectic mixture of lidocaine and other compounds, delivers controllable quantity of anesthetic to the penis and delays ejaculation.
The treatment is in compliance with the FDA monograph, ‘External Analgesic Drug Products for OTC Human Use’ under the OTC monograph 21 CFR Part 348.